Xilio Therapeutics (XLO) Treasury Shares (2020 - 2026)
Xilio Therapeutics (XLO) reported Treasury Shares of $15914.0 for Q1 2026, down 95.24% on a YoY basis from $334125.0 in Q1 2025, and down 33.32% sequentially from $23866.0 in Q4 2025.
Xilio Therapeutics (XLO) Treasury Shares (2020 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 7 years of Treasury Shares data on file, last reported at $15914.0 in Q1 2026.
- For the quarter ending Q1 2026, Treasury Shares fell 95.24% year-over-year to $15914.0; the trailing twelve-month figure through Mar 2026 stood at $15914.0 (down 95.24% YoY), and the FY2025 full-year result was $23866.0, down 24.99% from the prior year.
- Treasury Shares declined to $15914.0 in Q1 2026, from $23866.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $481500.0 in Q1 2024 to a low of $5617.0 in Q4 2023.
- A 5-year average of $164831.1 and a median of $64458.0 in 2022 frame the typical range for Treasury Shares.
- Across the five-year window, Treasury Shares sank 99.91% in 2022 and jumped 3307.53% in 2024, its largest moves.
- Tracing XLO's Treasury Shares over 5 years: stood at $46160.0 in 2022, then tumbled by 87.83% to $5617.0 in 2023, then jumped by 466.46% to $31818.0 in 2024, then decreased by 24.99% to $23866.0 in 2025, then plunged by 33.32% to $15914.0 in 2026.
- Business Quant data shows XLO's Treasury Shares at $15914.0 in Q1 2026, $23866.0 in Q4 2025, and $334125.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | 265,401.92 |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | 19.41 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | - |
| 10 | Xilio Therapeutics | 144.68 Mn | -5.62 Mn | - | 15,914.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,914.00 |
| Mar 31, 2026 | 15,914.00 |
| Dec 31, 2025 | 23,866.00 |
| Dec 31, 2025 | 23,866.00 |
| Sep 30, 2025 | 334,125.00 |
| Sep 30, 2025 | 334,125.00 |
| Jun 30, 2025 | 334,125.00 |
| Jun 30, 2025 | 334,125.00 |
| Mar 31, 2025 | 334,125.00 |
| Mar 31, 2025 | 334,125.00 |
| Dec 31, 2024 | 31,818.00 |
| Dec 31, 2024 | 31,818.00 |
| Sep 30, 2024 | 445,500.00 |
| Sep 30, 2024 | 445,500.00 |
| Jun 30, 2024 | 445,500.00 |
| Jun 30, 2024 | 445,500.00 |
| Mar 31, 2024 | 481,500.00 |
| Mar 31, 2024 | 481,500.00 |
| Dec 31, 2023 | 5,617.00 |
| Dec 31, 2023 | 5,617.00 |